Benefits and Risks of CT Angiography Immediately after Emergency Arrival for Patients with Intracerebral Hematoma.


Journal

Neurologia medico-chirurgica
ISSN: 1349-8029
Titre abrégé: Neurol Med Chir (Tokyo)
Pays: Japan
ID NLM: 0400775

Informations de publication

Date de publication:
15 Jan 2020
Historique:
pubmed: 12 11 2019
medline: 20 11 2020
entrez: 12 11 2019
Statut: ppublish

Résumé

Computed tomography angiography (CTA) immediately after diagnosis of intracerebral hematoma (ICH) on noncontrast CT in the emergency room has benefits, which consist of early diagnosis of secondary ICH and prediction of hematoma growth using the spot sign in primary ICH, but CTA also involves possible risks of acute kidney injury (AKI) and adverse reactions. The purpose of this study was to evaluate the benefits and risks of CTA. A total of 1423 consecutive adult patients diagnosed with ICH who were admitted within 3 days of onset between 2010 and 2017 were retrospectively analyzed. Of 1082 patients undergoing CTA, 162 patients (15.0%) showed secondary ICH, and the sensitivity of CTA for secondary ICH was 95.7%. Of 920 patients with primary ICH, a logistic regression model using the spot sign and four other previously reported risk factors (antiplatelet agents, anticoagulants, interval from onset to arrival, hematoma volume) with an area under the curve (AUC) of 0.787 significantly improved model performance to predict hematoma growth compared with a model using the same four factors without the spot sign (AUC: 0.697) (DeLong's test: P = 0.0002). Rates of AKI occurrence were 9.0% and 9.8% in patients with and without CTA, respectively. The odds ratio of AKI in patients with CTA adjusted by reported risk factors was 1.16 (95% confidence interval: 0.72-1.95, P = 0.5548). Emergency CTA following noncontrast CT in patients with ICH could be useful for early diagnosis of secondary ICH and prediction of hematoma growth using the spot sign in primary ICH with little risk.

Identifiants

pubmed: 31708512
doi: 10.2176/nmc.oa.2019-0152
pmc: PMC6970072
doi:

Substances chimiques

Contrast Media 0
Creatinine AYI8EX34EU

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

45-52

Références

J Neurosurg. 2012 Oct;117(4):761-6
pubmed: 22880718
World Neurosurg. 2019 Mar;123:e740-e746
pubmed: 30579025
Stroke. 2015 Jul;46(7):2032-60
pubmed: 26022637
Bone Marrow Transplant. 2013 Mar;48(3):452-8
pubmed: 23208313
Stroke. 2013 Jul;44(7):1830-2
pubmed: 23674525
J Neurol Neurosurg Psychiatry. 2018 Jul;89(7):674-679
pubmed: 29348301
Lancet Neurol. 2012 Apr;11(4):307-14
pubmed: 22405630
BMJ. 2015 Nov 09;351:h5762
pubmed: 26553142
Cerebrovasc Dis. 2018;45(1-2):1-9
pubmed: 29176313
Cochrane Database Syst Rev. 2014 Sep 01;(9):CD009372
pubmed: 25177839
PLoS One. 2014 Dec 26;9(12):e115777
pubmed: 25541717
Emerg Radiol. 2009 May;16(3):195-201
pubmed: 19132425
AJNR Am J Neuroradiol. 2009 Jun;30(6):1213-21
pubmed: 19342546
Radiology. 2013 Apr;267(1):106-18
pubmed: 23360742
Stroke. 2008 Apr;39(4):1177-83
pubmed: 18292380
Stroke. 2017 Jul;48(7):1862-1868
pubmed: 28583996
AJR Am J Roentgenol. 2009 Oct;193(4):1124-7
pubmed: 19770337
Lancet Neurol. 2018 Oct;17(10):885-894
pubmed: 30120039
AJNR Am J Neuroradiol. 2009 May;30(5):962-7
pubmed: 19193746
Eur Radiol. 1999;9(8):1602-13
pubmed: 10525875

Auteurs

Takatoshi Sorimachi (T)

Department of Neurosurgery, School of Medicine, Tokai University.

Hideki Atsumi (H)

Department of Neurosurgery, School of Medicine, Tokai University.

Takuya Yonemochi (T)

Department of Neurosurgery, School of Medicine, Tokai University.

Akihiro Hirayama (A)

Department of Neurosurgery, School of Medicine, Tokai University.

Hideaki Shigematsu (H)

Department of Neurosurgery, School of Medicine, Tokai University.

Kittipong Srivatanakul (K)

Department of Neurosurgery, School of Medicine, Tokai University.

Shunya Takizawa (S)

Department of Neurology, School of Medicine, Tokai University.

Mitsunori Matsumae (M)

Department of Neurosurgery, School of Medicine, Tokai University.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH